The Food and Drug Administration has rejected a closely watched cancer drug from Akeso and Summit Therapeutics, arguing that the therapy needed to extend patients’ lives in clinical testing to earn an approval.
U.S. regulators determined that the ability of Akeso and Summit’s ivonescimab to help delay tumor progression in a late-stage study in lung cancer wasn’t, on its own, enough to “support a positive benefit-risk profile,” the Miami-based biotech said in a Sunday statement.
Summit asked the FDA to approve a combination of ivonescimab and chemotherapy in people with EGFR-mutated, non-small cell lung cancer. In the “HARMONi” study, the company tested that combination against chemotherapy alone in people whose disease had progressed following treatment with a targeted therapy. But while Summit found that the ivonescimab-chemo regimen slowed disease progression or death by more than two months, it also reported that the combination didn’t clearly lengthen lives upon a primary trial analysis.
An after-the-fact evaluation - which included more participants enrolled from trial sites outside of Asia - revealed a survival benefit. The FDA didn’t accept those results, however, leading Summit to argue in its statement that its drug had been held to a higher bar than other available medicines for EGFR-mutated lung cancer. No other FDA-approved regimens have demonstrated a survival benefit in this particular treatment setting, Summit said.
“We are disappointed for patients and their families awaiting additional treatment options in this setting,” said Summit chairman and co-CEO Robert Duggan, in the statement. “We chose to pursue an ivonescimab regimen here based on the opportunity to provide another treatment option to help patients in need. In doing so, we believe the global HARMONi study provided the basis for a treatment option that these patients needed.”
Summit shares declined by 6% on Friday, ahead of the FDA’s decision deadline, and then plunged another 15% on Monday. Ivonescimab’s inventor Akeso, which licensed most rights to Summit in 2022, saw its own Hong Kong-traded shares fall 22% on Monday.
Ivonescimab is one of the most closely watched drugs in oncology research. In 2024, it burst forth with a trial result showing it had bested Merck & Co.’s widely used cancer immunotherapy Keytruda in lung cancer. That finding sparked a flurry of investments in drugs that, like ivonescimab, target two proteins called PD-1 and VEGF that drive cancer growth.
Ivonescimab has met many of the weighty expectations investors have placed on it in studies that have emerged since. Still, many of the key findings supporting ivonescimab have come from studies in China, leaving lingering doubts about its potential. Critics have noted that subtle differences in trial designs and enrollment criteria may have inflated ivonescimab’s impact.
In EGFR-mutated lung cancer, specifically, Wall Street analysts were divided about ivonescimab’s approval prospects. TD Cowen’s Tyler Van Buren argued that the eventual survival benefit Summit detected should be enough to support an approval. Leerink Partners analyst Daina Graybosch, however, had pointed to an explicit statement from the FDA that such a benefit had to be detected at the study’s primary analysis.
In a client note Sunday, Van Buren wrote that the decision is “disappointing” but “is consistent with the high bar FDA had previously communicated.”
Graybosch, meanwhile, wrote that the verdict suggests that the survival findings observed in other China-only studies weren’t enough to overcome what was seen in the global HARMONi trial. That means that, in the future, Summit might not be able to rely on the results of a China study called HARMONi-6 to support a lung cancer filing in a different setting, she wrote.
Van Buren and Graybosch noted that a bigger and more important test is quickly approaching. By the end of the year, Summit and Akeso should report results from a study testing ivonescimab and chemo against Keytruda and chemo in first-line lung cancer.
The FDA rejection “should have limited read-through to the larger ... opportunity,” Van Buren wrote.